Rob Davis is chief executive officer and president of Merck.
Previously, Rob served as Merck’s president, responsible for the company’s operating divisions — Human Health, Animal Health, Manufacturing and Merck Research Laboratories. Prior to that, he was executive vice president, Global Services, and the company’s chief financial officer.
Rob joined the company as chief financial officer in 2014 with additional responsibility for real estate operations, corporate strategy and business development. In 2016, his role was expanded to include responsibility for information technology and procurement, forming Global Services. He became president in April 2021 and CEO and a member of the board of directors on July 1, 2021.
Prior to joining Merck, Rob was corporate vice president and president of Baxter’s Medical Products business. During his tenure at Baxter, he held several other positions, including president of Baxter’s Renal business, chief financial officer and treasurer. Before joining Baxter in 2004, Rob held numerous positions of increasing responsibility over 14 years at Eli Lilly and Company.
Rob serves on the board of directors for Duke Energy Corporation and is chair of its finance and risk management committee and a member of the corporate governance committee. In addition, Rob is a board member of Project Hope, a non-profit organization focused on empowering health care workers to deliver expert care when and where it is needed most.
Rob received his J.D. from Northwestern University School of Law, his M.B.A. from Northwestern University’s Kellogg Graduate School of Management and his bachelor’s degree in finance from Miami University.
What is Robert M. Davis' net worth?
The estimated net worth of Robert M. Davis is at least $26.09 million as of November 9th, 2022. Mr. Davis owns 247,593 shares of Merck & Co., Inc. stock worth more than $26,091,350 as of January 30th. This net worth approximation does not reflect any other investments that Mr. Davis may own. Learn More about Robert M. Davis' net worth.
What is Robert M. Davis' salary?
As the CFO of Merck & Co., Inc., Mr. Davis earned a total compensation package of $13,722,121.00 in 2021. Mr. Davis earned a salary of $1,319,959.00, stock awards of $6,324,576.00, options awards of $2,760,003.00, non-equity compensation of $2,834,606.00, and other compensation of $247,337.00. Learn More on Robert M. Davis' salary.
How do I contact Robert M. Davis?
Has Robert M. Davis been buying or selling shares of Merck & Co., Inc.?
Robert M. Davis has not been actively trading shares of Merck & Co., Inc. during the past quarter. Most recently, Robert M. Davis sold 167,613 shares of the business's stock in a transaction on Wednesday, November 9th. The shares were sold at an average price of $102.44, for a transaction totalling $17,170,275.72. Following the completion of the sale, the chief executive officer now directly owns 247,593 shares of the company's stock, valued at $25,363,426.92. Learn More on Robert M. Davis' trading history.
Who are Merck & Co., Inc.'s active insiders?
Merck & Co., Inc.'s insider roster includes Sanat Chattopadhyay (Insider), Frank Clyburn (EVP), Robert Davis (CFO), Richard Deluca (EVP), Kenneth Frazier (Insider), Julie Gerberding (EVP), Clark Golestani (EVP), Michael Holston (EVP), Rita Karachun (VP), Caroline Litchfield (CFO), Ashley Watson (SVP), and Wendell Weeks (Director). Learn More on Merck & Co., Inc.'s active insiders.
Are insiders buying or selling shares of Merck & Co., Inc.?
During the last year, insiders at the sold shares 11 times. They sold a total of 1,165,809 shares worth more than $118,007,119.60. The most recent insider tranaction occured on January, 9th when insider Sanat Chattopadhyay sold 83,994 shares worth more than $9,431,686.26. Insiders at Merck & Co., Inc. own 0.3% of the company.
Learn More about insider trades at Merck & Co., Inc.. Information on this page was last updated on 1/9/2023.
